Volume 85 Issue 10 | p. 29 | Concentrates
Issue Date: March 5, 2007

Dowpharma Signs Drug Technology Deals

Department: Business

Merck and Serum Institute of India have separately licensed Dowpharma's Pfenex technology, a Pseudomonas fluorescens-based fermentation method for making proteins. Dowpharma has developed a high-yielding strain that Merck will use to produce a protein vaccine component. The agreement with Merck also covers other proteins for use in human medicines. Meanwhile, Serum Institute will use the technology to produce an unspecified protein for its vaccine products.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment